Ki-Hong Kim

Title: **Inventor Spotlight: Ki-Hong Kim**

Introduction

Ki-Hong Kim is an innovative inventor based in Changwon-si, South Korea. His work is centered around advancements in biotechnology, specifically focusing on immunology. His contributions have been instrumental in developing novel therapeutic solutions.

Latest Patents

Ki-Hong Kim holds one patent titled "IL-32 monoclonal antibodies and uses thereof." This patent presents monoclonal antibodies that are specific to interleukin-32 (IL-32), previously known as 'natural killer cell transcript 4' or 'NK4.' The invention includes hybridomas that secrete these specific monoclonal antibodies, alongside diagnostic methods and kits, such as ELISA and Western blot, which leverage the unique properties of these antibodies for various applications.

Career Highlights

Ki-Hong Kim currently works at the Konkuk University Industrial Cooperation Corporation, where his research and development initiatives contribute to the advancement of biotechnological innovations. With his expertise in immunology, he continues to explore the clinical applications of his findings, aiming to improve healthcare outcomes through targeted therapies.

Collaborations

Throughout his career, Ki-Hong Kim has collaborated with notable colleagues, including Jung-Hyun Shim and Min-chul Cho. These partnerships foster a rich research environment that promotes the exchange of ideas and synergistic efforts towards groundbreaking discoveries in the field of biotechnology.

Conclusion

Ki-Hong Kim exemplifies the spirit of innovation in the biotechnological sector. His work on IL-32 monoclonal antibodies is a testament to the impact that dedicated inventors can have on scientific progress and public health. As he continues to develop new methodologies, his contributions will likely open up further avenues for research and therapeutic solutions.